UnknownPhase 2NCT00005959
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amgen
- Principal Investigator
- Carol Brannan, BS, BSNAmgen
- Intervention
- filgrastim(biological)
- Eligibility
- 18 years · All sexes
- Timeline
- 1999
Study locations (27)
- Montgomery Cancer Center, Montgomery, Alabama, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
- Cancer and Blood Institute of the Desert, Rancho Mirage, California, United States
- Southeast Florida Hematology-Oncology Group, Fort Lauderdale, Florida, United States
- Oncology-Hematology Group of South Florida, Miami, Florida, United States
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- Hematology-Oncology Associates, PA, Pensacola, Florida, United States
- Hutchinson Clinic, P.A., Hutchinson, Kansas, United States
- Hematology/Oncology Care Inc., Crestview Hills, Kentucky, United States
- Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States
- Associates in Oncology and Hematology, Rockville, Maryland, United States
- North Shore Cancer Center, Peabody, Massachusetts, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Lakeland Medical Center - St. Joseph, Saint Joseph, Michigan, United States
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005959 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital